Pharmexon
Prague-based life sciences consultancy (founded 2016) providing expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, and pharmaceutical translation services to pharmaceutical, biotech, and medical device companies across Europe, the UK, North America, and APAC.
- Company typePrivate
- Founded2016
- HeadquartersPrague, Czechia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Pharmexon does
Pharmexon Consulting s.r.o. is a Prague-based life sciences consultancy, incorporated in the Czech Republic in 2016 (Company No. 05267846), that provides expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, authoring/technical review, and pharmaceutical translation services to pharmaceutical, biotechnology, and medical device companies across Europe, the UK, North America, and APAC. Its service offering spans the full product lifecycle — from pre-development pathway planning and clinical/non-clinical/CMC consultancy through Marketing Authorisation Applications (national, DCP, MRP, CP), variations, renewals, and post-marketing pharmacovigilance (PSMF, EUQPPV, LQPPV, xEVMPD). The company does not develop proprietary technology platforms; its core "asset" is a bench of senior experts, including former regulators from INFARMED, MHRA, the Estonian State Agency of Medicines, and WHO Medicines Prequalification, with documented representation at EMA committees (CMDh) — a positioning the firm markets as its "4D Approach."
The firm operates a sales-led B2B motion targeting enterprise pharma clients through direct engagement, a dedicated business development contact, conference presence at CPHI Worldwide and BioBridges, a LinkedIn company page, and a monthly Regulatory Intelligence blog. Revenue is generated entirely on a professional services basis — project-based consulting engagements, ongoing PV service contracts, and multi-year retainers — with pricing quoted per project scope and not publicly disclosed. Notable enterprise clients include Polpharma, Italfarmaco Group, Grindex, Remedica Ltd, ProActiona SA, and GL Pharma, several of which describe multi-year relationships and characterize the firm as an extension of their internal regulatory teams. Operational quality is anchored by ISO 9001:2015 (November 2023) and ISO 17100 (February 2023) certifications, and the firm is independently owned by co-founders Parvinder Punia (Head of Regulatory Affairs & Pharmacovigilance) and Laura Nae, with no disclosed external investors, parent company, or M&A activity.
Pharmexon firmographics
Firmographics- Name
- Pharmexon
- Legal name
- Pharmexon Consulting s.r.o.
- Website
- https://pharmexon.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Prague-based life sciences consultancy (founded 2016) providing expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, and pharmaceutical translation services to pharmaceutical, biotech, and medical device companies across Europe, the UK, North America, and APAC.
- Ownership category
- akta.pro rank
Pharmexon industry classification
Industry- Product category
- Life Sciences Regulatory Consulting
- NAICS
- Other Management Consulting Services (541618)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Pharmexon is headquartered
LocationHeadquarters
- HQ city
- Prague
- HQ country
- Czechia
- HQ region
- Europe
Offices1 record
Markets served
Pharmexon business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Regulatory Affairs Consulting: Professional consulting services for regulatory strategy, marketing authorisation applications, submission management, and regulatory compliance across EU, FDA, and global markets. Revenue generated through project-based consulting engagements and retainer arrangements.
- Pharmacovigilance Services: Comprehensive PV services including PSMF management, EUQPPV provision, safety database management, and local PV services. Billed as ongoing service contracts or per-project engagements.
- Translation Services: Specialized pharmaceutical and medical translation services including linguistic reviews, harmonization of product information, and artwork/mock-ups creation for regulatory compliance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Pharmexon product offering
Product offeringCore offering
Pharmexon is a life sciences consultancy that delivers expert regulatory affairs, pharmacovigilance, safety writing, authoring and technical review, ex-agency consulting, and pharmaceutical translation services. It supports pharmaceutical, biotech, and medical device companies across the full product lifecycle — from pre-development pathways and compliant documentation through to marketing authorisation applications, post-marketing maintenance, and pharmacovigilance operations across the EU, UK, US, Canada, and APAC markets.
Product overview
Pharmexon is a life sciences consultancy offering a comprehensive portfolio of regulatory affairs, pharmacovigilance, safety writing, and translation services. The company operates as a service-based consultancy (not a single software product) with distinct service lines including Regulatory Affairs Services (covering MAAs, submissions, variations, renewals), Pharmacovigilance Services (PV systems, EUQPPV, PSMF management), Local PV Services (LQPPV, local monitoring), Safety Writing and Management, Authoring and Technical Review Services, Ex-Agency Consulting Services, and Translation Services. These services work together to support pharmaceutical companies through pre-development, development, registration, and post-marketing lifecycle management of medicines and medical devices.
Differentiator
Problem solved
Functional benefit
Products and services
- Regulatory Affairs Services
Quantifiable outcome
- Successfully concluded CMDh referral on Day 60 with positive outcome; CMDh initiated guideline revision as result of case
- +3 more outcomes
Companies that use Pharmexon
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Pharmexon technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Pharmexon partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
Pharmexon competitors and assessment
Company assessmentBroad incumbents
- Parexel: Large global CRO with dedicated regulatory affairs and pharmacovigilance consulting practices. Overlaps with Pharmexon on MAA submissions, lifecycle management, and PV services, but typically serves larger enterprise pharma clients.
- ICON plc: Global CRO offering integrated clinical, regulatory, and pharmacovigilance services at scale. Competes with Pharmexon for regulatory affairs and PV mandates, particularly for mid-to-large pharma running multi-region submissions.
- Premier Research: Mid-sized global CRO with regulatory and pharmacovigilance service lines. Overlaps with Pharmexon on regulatory strategy and lifecycle management but generally pairs these with clinical trial execution capabilities Pharmexon does not offer.
- IQVIA: World's largest CRO with regulatory and safety service lines bundled into broader clinical and commercial offerings. Competes with Pharmexon in regulatory affairs and PV but at a vastly larger scale and with technology-enabled delivery.
Direct peers
- ProPharma Group: Regulatory compliance, pharmacovigilance, and medical information consultancy serving pharma, biotech, and medical device companies. Comparable to Pharmexon in its consulting-led model and focus on regulatory strategy and lifecycle maintenance.
- Arriello: Specialist regulatory affairs, pharmacovigilance, and quality/compliance consultancy for life sciences, with strong ex-agency talent and pan-European coverage. Directly comparable to Pharmexon in scope of services, target mid-cap pharma clients, and ex-regulator positioning.
- Voisin Consulting Life Sciences: Regulatory and clinical development consultancy with deep expertise in EMA, FDA, and global submission strategy. Comparable to Pharmexon in regulatory affairs focus and ex-agency positioning, with overlapping service lines in MAA management and scientific advice.
- PharmaLex (Cencora): Specialized regulatory affairs, pharmacovigilance, and quality management consultancy serving small and mid-cap pharma and biotech. Closest functional peer to Pharmexon across MAA submissions, PV systems, and lifecycle management, now scaled globally through Cencora ownership.
Emerging players
- Pharma Assist (Europe): European regulatory and pharmacovigilance consultancy serving pharma and biotech. Comparable niche focus to Pharmexon on EU MAA management, variations, and PV services for mid-cap clients.
- Regulis Consulting: Boutique European regulatory affairs and pharmacovigilance consultancy. Comparable to Pharmexon in its niche focus on EU regulatory strategy and PV services for mid-cap pharma and biotech clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pharmexon social profiles
Digital presencePharmexon compliance and trust
Trust signalCompliance2 records
Pharmexon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharmexon leadership team
Management profileNumber of profiles
Profiles5 records
Pharmexon funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharmexon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharmexon
What does Pharmexon do?
Pharmexon is a life sciences consultancy that delivers expert regulatory affairs, pharmacovigilance, safety writing, authoring and technical review, ex-agency consulting, and pharmaceutical translation services. It supports pharmaceutical, biotech, and medical device companies across the full product lifecycle — from pre-development pathways and compliant documentation through to marketing authorisation applications, post-marketing maintenance, and pharmacovigilance operations across the EU, UK, US, Canada, and APAC markets.
Is Pharmexon a public or private company?
Pharmexon is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Pharmexon founded?
Pharmexon was founded in 2016. It employs 11 to 50 people.
Where is Pharmexon based?
Pharmexon is headquartered in Prague, Czechia, in the Europe region.
How does Pharmexon make money?
Three revenue lines are on record. Regulatory Affairs Consulting is the primary driver. The others are pharmacovigilance Services and translation Services.
Who are Pharmexon's main competitors?
Broad incumbents on record are Parexel, ICON plc, Premier Research and IQVIA. Direct peers are ProPharma Group, Arriello, Voisin Consulting Life Sciences and PharmaLex (Cencora). Emerging players are Pharma Assist (Europe) and Regulis Consulting.
Does Pharmexon have an API?
No public API is recorded for Pharmexon.
What industry is Pharmexon in?
Pharmexon's product category is Life Sciences Regulatory Consulting. Its primary akta.pro industry code is HLAGAAAH, Pharmacovigilance, Risk Management & Medical Affairs CROs, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 541618 and its SIC code is 8731.